Spotlight on Endocrinology & Diabetes

Credits: 0.50 CME
The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown – How Do I Identify Patients at Risk of Hypoglycemia?
Kathleen Dungan, MD, MPH
Academy for Continued Healthcare Learning

The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown – How Do I Identify Patients at Risk of Hypoglycemia?

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)™
Released: September 4, 2020
Expires: September 4, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify barriers to recognizing and treating severe hypoglycemia
  • Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
  • Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes

Activity Description

Dr. Kathleen Dungan presents a patient case and shares her personal approach used in clinical practice. She discusses how to identify patients at risk of hypoglycemia, with a focus on risk factors, ADA guidelines, individualizing A1c targets, and COVID-19 implications.

Statement of Education Need

Despite an array of advances in diabetes care over the last decade, hypoglycemia remains a common complication of diabetes treatment. Hypoglycemia and the fear of future episodes can be extremely detrimental to quality of life. This activity will review strategies to minimize the risk of hypoglycemia, improve recognition of severe hypoglycemia, and improve guideline adherence to address underutilization of glucagon in patients at risk for level 2 hypoglycemia.

Agenda

CASE #1: How do I identify patients at risk of hypoglycemia?

  1. Patient case: exercise program
  2. Discussion of risk factors for hypoglycemia
  3. Barriers to recognizing and treating severe hypoglycemia: intensive control, alcohol, exercise
  4. ADA guidelines for glycemic targets
  5. Preemptive strategies for severe hypoglycemia: individualize glycemic targets, prescribe glucagon, educate patient on risk factors
  6. COVID-19 implications

Faculty

Kathleen Dungan, MD, MPH
Professor, Associate Director Clinical Services
Director Endocrine Clinical Trials
The Ohio State University
Columbus, OH

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Kathleen Dungan, MD, MPH
Sources of Funding for Research: Novo Nordisk, Sanofi Aventis
Consulting Agreements: Eli Lilly
Speaker: Nova Biomedical
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Melissa Stradal at mstradal@achlcme.org

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)™
Released: September 4, 2020
Expires: September 4, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify barriers to recognizing and treating severe hypoglycemia
  • Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
  • Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes

Activity Description

Dr. Kathleen Dungan presents a patient case and shares her personal approach used in clinical practice. She discusses how to identify patients at risk of hypoglycemia, with a focus on risk factors, ADA guidelines, individualizing A1c targets, and COVID-19 implications.

Statement of Education Need

Despite an array of advances in diabetes care over the last decade, hypoglycemia remains a common complication of diabetes treatment. Hypoglycemia and the fear of future episodes can be extremely detrimental to quality of life. This activity will review strategies to minimize the risk of hypoglycemia, improve recognition of severe hypoglycemia, and improve guideline adherence to address underutilization of glucagon in patients at risk for level 2 hypoglycemia.

Agenda

CASE #1: How do I identify patients at risk of hypoglycemia?

  1. Patient case: exercise program
  2. Discussion of risk factors for hypoglycemia
  3. Barriers to recognizing and treating severe hypoglycemia: intensive control, alcohol, exercise
  4. ADA guidelines for glycemic targets
  5. Preemptive strategies for severe hypoglycemia: individualize glycemic targets, prescribe glucagon, educate patient on risk factors
  6. COVID-19 implications

Faculty

Kathleen Dungan, MD, MPH
Professor, Associate Director Clinical Services
Director Endocrine Clinical Trials
The Ohio State University
Columbus, OH

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Kathleen Dungan, MD, MPH
Sources of Funding for Research: Novo Nordisk, Sanofi Aventis
Consulting Agreements: Eli Lilly
Speaker: Nova Biomedical
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Melissa Stradal at mstradal@achlcme.org

Endocrinology & Diabetes Presentations

0.25 CME
Academy for Continued Healthcare Learning
The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown – How Do I Manage Fear of Hypoglycemia?

The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown – How Do I Manage Fear of Hypoglycemia?

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)™
Released: September 4, 2020
Expires: September 4, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify barriers to recognizing and treating severe hypoglycemia
  • Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
  • Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes

Activity Description

Dr. Anne Peters presents a patient case and shares her personal approach used in clinical practice. She discusses how to manage fear of hypoglycemia, with a focus on how fear impacts behavior, measuring fear in patients, and preemptive strategies to reduce fear.

Statement of Education Need

Despite an array of advances in diabetes care over the last decade, hypoglycemia remains a common complication of diabetes treatment. Hypoglycemia and the fear of future episodes can be extremely detrimental to quality of life. This activity will review strategies to minimize the risk of hypoglycemia, improve recognition of severe hypoglycemia, and improve guideline adherence to address underutilization of glucagon in patients at risk for level 2 hypoglycemia.

Agenda

CASE #3: How do I manage fear of hypoglycemia?

  1. Patient case
  2. Barriers to recognizing and treating severe hypoglycemia: difficulty using injectable glucagon
  3. ADA guidelines for hypoglycemia
  4. Preemptive strategies for severe hypoglycemia: patient and caregiver education

Faculty

Anne Peters, MD
Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
Keck School of Medicine of USC
Los Angeles, CA

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Anne Peters, MD
Sources of Funding for Research: Dexcom, vTv Therapeutics, donated devices from Abbott Diabetes Care
Advisory Board: Abbott Diabetes Care, Boehringer Ingelheim, Eli Lilly and Co., Livongo, MannKind, Merck, Novo Nordisk, Sanofi, Pendulum Therapeutics
Stock Options: Mellitus Health, Livongo, Omada Health, Pendulum Therapeutics, Stability Health
Speakers' Bureau: Novo Nordisk
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Melissa Stradal at mstradal@achlcme.org

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)™
Released: September 4, 2020
Expires: September 4, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify barriers to recognizing and treating severe hypoglycemia
  • Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
  • Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes

Activity Description

Dr. Anne Peters presents a patient case and shares her personal approach used in clinical practice. She discusses how to manage fear of hypoglycemia, with a focus on how fear impacts behavior, measuring fear in patients, and preemptive strategies to reduce fear.

Statement of Education Need

Despite an array of advances in diabetes care over the last decade, hypoglycemia remains a common complication of diabetes treatment. Hypoglycemia and the fear of future episodes can be extremely detrimental to quality of life. This activity will review strategies to minimize the risk of hypoglycemia, improve recognition of severe hypoglycemia, and improve guideline adherence to address underutilization of glucagon in patients at risk for level 2 hypoglycemia.

Agenda

CASE #3: How do I manage fear of hypoglycemia?

  1. Patient case
  2. Barriers to recognizing and treating severe hypoglycemia: difficulty using injectable glucagon
  3. ADA guidelines for hypoglycemia
  4. Preemptive strategies for severe hypoglycemia: patient and caregiver education

Faculty

Anne Peters, MD
Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
Keck School of Medicine of USC
Los Angeles, CA

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Anne Peters, MD
Sources of Funding for Research: Dexcom, vTv Therapeutics, donated devices from Abbott Diabetes Care
Advisory Board: Abbott Diabetes Care, Boehringer Ingelheim, Eli Lilly and Co., Livongo, MannKind, Merck, Novo Nordisk, Sanofi, Pendulum Therapeutics
Stock Options: Mellitus Health, Livongo, Omada Health, Pendulum Therapeutics, Stability Health
Speakers' Bureau: Novo Nordisk
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Melissa Stradal at mstradal@achlcme.org

0.50 CME
Academy for Continued Healthcare Learning
The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown – How Do I Identify Patients at Risk of Hypoglycemia?

The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown – How Do I Identify Patients at Risk of Hypoglycemia?

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)™
Released: September 4, 2020
Expires: September 4, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify barriers to recognizing and treating severe hypoglycemia
  • Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
  • Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes

Activity Description

Dr. Kathleen Dungan presents a patient case and shares her personal approach used in clinical practice. She discusses how to identify patients at risk of hypoglycemia, with a focus on risk factors, ADA guidelines, individualizing A1c targets, and COVID-19 implications.

Statement of Education Need

Despite an array of advances in diabetes care over the last decade, hypoglycemia remains a common complication of diabetes treatment. Hypoglycemia and the fear of future episodes can be extremely detrimental to quality of life. This activity will review strategies to minimize the risk of hypoglycemia, improve recognition of severe hypoglycemia, and improve guideline adherence to address underutilization of glucagon in patients at risk for level 2 hypoglycemia.

Agenda

CASE #1: How do I identify patients at risk of hypoglycemia?

  1. Patient case: exercise program
  2. Discussion of risk factors for hypoglycemia
  3. Barriers to recognizing and treating severe hypoglycemia: intensive control, alcohol, exercise
  4. ADA guidelines for glycemic targets
  5. Preemptive strategies for severe hypoglycemia: individualize glycemic targets, prescribe glucagon, educate patient on risk factors
  6. COVID-19 implications

Faculty

Kathleen Dungan, MD, MPH
Professor, Associate Director Clinical Services
Director Endocrine Clinical Trials
The Ohio State University
Columbus, OH

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Kathleen Dungan, MD, MPH
Sources of Funding for Research: Novo Nordisk, Sanofi Aventis
Consulting Agreements: Eli Lilly
Speaker: Nova Biomedical
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Melissa Stradal at mstradal@achlcme.org

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)™
Released: September 4, 2020
Expires: September 4, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify barriers to recognizing and treating severe hypoglycemia
  • Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
  • Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes

Activity Description

Dr. Kathleen Dungan presents a patient case and shares her personal approach used in clinical practice. She discusses how to identify patients at risk of hypoglycemia, with a focus on risk factors, ADA guidelines, individualizing A1c targets, and COVID-19 implications.

Statement of Education Need

Despite an array of advances in diabetes care over the last decade, hypoglycemia remains a common complication of diabetes treatment. Hypoglycemia and the fear of future episodes can be extremely detrimental to quality of life. This activity will review strategies to minimize the risk of hypoglycemia, improve recognition of severe hypoglycemia, and improve guideline adherence to address underutilization of glucagon in patients at risk for level 2 hypoglycemia.

Agenda

CASE #1: How do I identify patients at risk of hypoglycemia?

  1. Patient case: exercise program
  2. Discussion of risk factors for hypoglycemia
  3. Barriers to recognizing and treating severe hypoglycemia: intensive control, alcohol, exercise
  4. ADA guidelines for glycemic targets
  5. Preemptive strategies for severe hypoglycemia: individualize glycemic targets, prescribe glucagon, educate patient on risk factors
  6. COVID-19 implications

Faculty

Kathleen Dungan, MD, MPH
Professor, Associate Director Clinical Services
Director Endocrine Clinical Trials
The Ohio State University
Columbus, OH

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Kathleen Dungan, MD, MPH
Sources of Funding for Research: Novo Nordisk, Sanofi Aventis
Consulting Agreements: Eli Lilly
Speaker: Nova Biomedical
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Melissa Stradal at mstradal@achlcme.org

0.50 CME
Academy for Continued Healthcare Learning
The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown – How Do I Manage Hypoglycemia Unawareness?

The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown – How Do I Manage Hypoglycemia Unawareness?

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)™
Released: September 4, 2020
Expires: September 4, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify barriers to recognizing and treating severe hypoglycemia
  • Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
  • Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes

Activity Description

Dr. Lawrence Blonde presents a patient case and shares his personal approach used in clinical practice. He discusses how to manage hypoglycemia unawareness with a focus on diagnosis, reversing impaired awareness, and preparing patients.

Statement of Education Need

Despite an array of advances in diabetes care over the last decade, hypoglycemia remains a common complication of diabetes treatment. Hypoglycemia and the fear of future episodes can be extremely detrimental to quality of life. This activity will review strategies to minimize the risk of hypoglycemia, improve recognition of severe hypoglycemia, and improve guideline adherence to address underutilization of glucagon in patients at risk for level 2 hypoglycemia.

Agenda

CASE #2: How do I manage hypoglycemia unawareness?

  1. Patient case
  2. Barriers to recognizing and treating severe hypoglycemia: hypoglycemia unawareness
  3. ADA guidelines for hypoglycemia unawareness
  4. Preemptive strategies for severe hypoglycemia: prescribe nasal glucagon and enroll in hypo awareness program

Faculty

Lawrence Blonde, MD, FACP, MACE
Director, Ochsner Diabetes Clinical Research Unit
Fran Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Lawrence Blonde, MD, FACP, MACE
Sources of Funding for Research: Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi
Consulting Agreements: AstraZeneca, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi
Speakers' Bureau: Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Melissa Stradal at mstradal@achlcme.org

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)™
Released: September 4, 2020
Expires: September 4, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify barriers to recognizing and treating severe hypoglycemia
  • Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
  • Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes

Activity Description

Dr. Lawrence Blonde presents a patient case and shares his personal approach used in clinical practice. He discusses how to manage hypoglycemia unawareness with a focus on diagnosis, reversing impaired awareness, and preparing patients.

Statement of Education Need

Despite an array of advances in diabetes care over the last decade, hypoglycemia remains a common complication of diabetes treatment. Hypoglycemia and the fear of future episodes can be extremely detrimental to quality of life. This activity will review strategies to minimize the risk of hypoglycemia, improve recognition of severe hypoglycemia, and improve guideline adherence to address underutilization of glucagon in patients at risk for level 2 hypoglycemia.

Agenda

CASE #2: How do I manage hypoglycemia unawareness?

  1. Patient case
  2. Barriers to recognizing and treating severe hypoglycemia: hypoglycemia unawareness
  3. ADA guidelines for hypoglycemia unawareness
  4. Preemptive strategies for severe hypoglycemia: prescribe nasal glucagon and enroll in hypo awareness program

Faculty

Lawrence Blonde, MD, FACP, MACE
Director, Ochsner Diabetes Clinical Research Unit
Fran Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Lawrence Blonde, MD, FACP, MACE
Sources of Funding for Research: Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi
Consulting Agreements: AstraZeneca, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi
Speakers' Bureau: Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Melissa Stradal at mstradal@achlcme.org

0.75 CME
Integrity Continuing Education, Inc.
Why Weight? The Family Practice Guide for Enhancing the Patient-Provider Connection in Obesity Management

Why Weight? The Family Practice Guide for Enhancing the Patient-Provider Connection in Obesity Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 31, 2020
Expires: July 31, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion​
  • Examine regional and ethnic disparities to tailor obesity interventions appropriately​
  • Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment​
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance

Activity Description

Obesity rates are increasing, and contrary to other major global risks, there is little evidence of successful population-level intervention strategies to reduce rates. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of clinicians. It is well known that there is a growing shortage of obesity specialists in the United States who diagnose and manage interrelated cardiometabolic diseases. Therefore, family practice physicians are expected to become the frontline providers to manage obesity in the near future.

A comprehensive, patient-centered approach to obesity improves patient outcomes, but rarely is implemented. In order for a patient-centered approach to be implemented, clinicians are required to know how to effectively engage their patients and be up-to-date on current medical anti-obesity therapies so they can select the most appropriate agent for their individual patient’s needs. This innovative activity will incorporate multiple evidence-based adult learning principles to improve family physicians' skills and confidence in weight-loss counseling and treatment.

Faculty

Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Gelesis, Medtronic, Novo Nordisk
Speakers’ BureausNovo Nordisk
Contracted Research: Novo Nordisk 

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2020 through July 31, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk, Inc.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 31, 2020
Expires: July 31, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion​
  • Examine regional and ethnic disparities to tailor obesity interventions appropriately​
  • Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment​
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance

Activity Description

Obesity rates are increasing, and contrary to other major global risks, there is little evidence of successful population-level intervention strategies to reduce rates. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of clinicians. It is well known that there is a growing shortage of obesity specialists in the United States who diagnose and manage interrelated cardiometabolic diseases. Therefore, family practice physicians are expected to become the frontline providers to manage obesity in the near future.

A comprehensive, patient-centered approach to obesity improves patient outcomes, but rarely is implemented. In order for a patient-centered approach to be implemented, clinicians are required to know how to effectively engage their patients and be up-to-date on current medical anti-obesity therapies so they can select the most appropriate agent for their individual patient’s needs. This innovative activity will incorporate multiple evidence-based adult learning principles to improve family physicians' skills and confidence in weight-loss counseling and treatment.

Faculty

Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Gelesis, Medtronic, Novo Nordisk
Speakers’ BureausNovo Nordisk
Contracted Research: Novo Nordisk 

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2020 through July 31, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk, Inc.